Business
NHS England commercial strategy for MT-RNR1
Genedrive plc has welcomed NHS England's preliminary market engagement notice regarding a commercial strategy for rapid MT-RNR1 testing in neonates, a development that could significantly impact its stock. This notice aims to inform the procurement process for tests designed to prevent antibiotic-induced hearing loss. The company's MT-RNR1 test has already been used by approximately 900 neonatal nurses for over 10,000 babies, potentially preventing over 30 cases of lifelong hearing loss. The Genedrive® MT-RNR1 ID kit is currently being implemented in 14 UK hospitals as part of a real-world evidence generation programme, with a conditional recommendation from NICE. Genedrive anticipates a tender notice publication date of January 1, 2027, and a go-live target date of July 1, 2027, contingent on NICE guidance. Disclaimer*
About this update from Genedrive Plc
21 April 2026 genedrive plc ("genedrive" or the "Company") Consultation to inform NHS England commercial strategy for rapid MT-RNR1 testing genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, welcomes publication from NHS England of a Preliminary market engagement notice under the Procurement Act 2023, to inform the NHS commercial strategy for rapid genetic MT-RNR1 testing in neonates to prevent antibiotic induced hearing loss. Dr Gino Miele, CEO of genedrive plc, said: "We welcome the communication of this premarket engagement by NHS England and the clarity it provides with respect to intended future commitment at a national level. To date, since introduction, our rapid MT-RNR1 test has been used as part of routine clinical practice by approximately 900 neonatal nurses for over 10,000 babies admitted to NICUs, enabling more than 30 to avoid lifelong hearing loss as a result of aminoglycoside antibiotic exposure. "As a UK-based diagnostics vendor, that has worked in close proximity with various NHS partners, we are proud to have developed and brought this product to a previously unaddressed clinical market of global significance, and look forward to all babies admitted to NICUs throughout the UK being able to benefit regardless of geographical residence. We believe we are uniquely positioned to address this anticipated tender and look forward to communicating progress in due course." In the UK, Genedrive® MT-RNR1 ID kit is being implemented and used in the Neonatal Intensive Care Units ("NICU") of 14 hospitals across the four UK nations as part of a real world evidence generation programme (PALOH-UK) funded by the National Institute for Health and Care Research (NIHR) and the UK Government Office for Life Sciences (OLS). The test also has conditional recommendation for use in the NHS by the National Institute for Health and Care Excellence ("NICE") whilst further real world evidence is generated. genedrive estimates that annual NICU admissions in these NICUs represent approximately 10% of admissions in the UK. Additionally, since October 2025, implementation of the Genedrive® MT-RNR1 ID kit into all NHS Scotland Health boards has been actively progressing under a phased implantation programme with the Accelerated National Innovation Adoption (ANIA) pathway led by the Sco...